Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis

• Main Authors: Van De Laar CJ (Author), Oude Voshaar MAH (Author), Fakhouri WKH (Author), Zaremba-Pechmann L (Author), De Leonardis F (Author), De La Torre I (Author), Van De Laar MAFJ (Author)
• Format: Book
• Published: Dove Medical Press, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Celine J Van De Laar,1 Martijn AH Oude Voshaar,1,2 Walid KH Fakhouri,3 Liliana Zaremba-Pechmann,3 Francesco De Leonardis,3 Inmaculada De La Torre,3 Mart AFJ Van De Laar1,2 1Transparency in Healthcare BV, Hengelo, the Netherlands; 2Department of Psychology and Communication of Health and Risk, Instit...